A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study

被引：0
|
作者：
Patrizia Vici
Giuseppe Colucci
Francesco Giotta
Domenico Sergi
Gianfranco Filippelli
Pasquale Perri
Claudio Botti
Enrico Vizza
Armando Carpino
Laura Pizzuti
Agnese Latorre
Diana Giannarelli
Massimo Lopez
Luigi Di Lauro
机构：
[1] Regina Elena National Cancer Institute,Division of Medical Oncology B
[2] Oncologic Institute,Department of Medical and Experimental Oncology
[3] Division of Medical Oncology,Division of Surgery A
[4] S. Francesco Hospital,Division of Gynecological Oncology
[5] Regina Elena National Cancer Institute,Cardiologic Unit
[6] Regina Elena National Cancer Institute,Biostatistics Unit
[7] Regina Elena National Cancer Institute,undefined
[8] Regina Elena National Cancer Institute,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 30卷
关键词：
Anthracyclines; Lapatinib; Pegylated Liposomal Doxorubicin; Neutropenic Fever; Advanced Breast Cancer Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 49 条
  • [1] Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer
    Mlineritsch, Brigitte
    Schabel-Moser, Renate
    Andel, Johannes
    Fridrik, Michael
    Moik, Martin
    Mayer, Peter
    Russ, Gudrun
    Rass, Christof
    Greil, Richard
    ONKOLOGIE, 2009, 32 (1-2): : 18 - 24
  • [2] Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
    Livi, L.
    Meattini, I.
    Scotti, V.
    Cardillo, C. De Luca
    Galardi, A.
    Iermano, C.
    Sanchez, L.
    Nori, J.
    Mangoni, M.
    Franzese, C.
    Orzalesi, L.
    Bertocci, S.
    Agresti, B.
    Masoni, T.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (03) : 158 - 162
  • [3] Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
    Alexopoulos, A
    Karamouzis, MV
    Stavrinides, H
    Ardavanis, A
    Kandilis, K
    Stavrakakis, J
    Georganta, C
    Rigatos, G
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 891 - 895
  • [4] A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
    Harbeck, Nadia
    Saupe, Steffen
    Jaeger, Elke
    Schmidt, Marcus
    Kreienberg, Rolf
    Mueller, Lothar
    Otremba, Burkhard Joerg
    Waldenmaier, Dirk
    Dorn, Julia
    Warm, Mathias
    Scholz, Michael
    Untch, Michael
    de Wit, Maike
    Barinoff, Jana
    Lueck, Hans-Joachim
    Harter, Philipp
    Augustin, Doris
    Harnett, Paul
    Beckmann, Matthias W.
    Al-Batran, Salah-Eddin
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (01) : 63 - 72
  • [5] Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer
    Blasinska-Morawiec, Maria
    Tubiana-Mathieu, Nicole
    Fougeray, Ronan
    Pinel, Marie-Claire
    Bougnoux, Philippe
    BREAST, 2013, 22 (01): : 58 - 63
  • [6] A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
    Nadia Harbeck
    Steffen Saupe
    Elke Jäger
    Marcus Schmidt
    Rolf Kreienberg
    Lothar Müller
    Burkhard Joerg Otremba
    Dirk Waldenmaier
    Julia Dorn
    Mathias Warm
    Michael Scholz
    Michael Untch
    Maike de Wit
    Jana Barinoff
    Hans-Joachim Lück
    Philipp Harter
    Doris Augustin
    Paul Harnett
    Matthias W. Beckmann
    Salah-Eddin Al-Batran
    Breast Cancer Research and Treatment, 2017, 161 : 63 - 72
  • [7] Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
    Bourgeois, Hugues
    Ferru, Aurelie
    Lortholary, Alain
    Delozier, Thierry
    Boisdron-Celle, Michelle
    Abadie-Lacourtoisie, Sophie
    Joly, Florence
    Chieze, Stephanie
    Chabrun, Virginie
    Gamelin, Erick
    Tourani, Jean-Marc
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (03): : 267 - 275
  • [8] Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients
    Kurtz, J. E.
    Rousseau, F.
    Meyer, N.
    Delozier, T.
    Serin, D.
    Nabet, M.
    Djafari, L.
    Dufour, P.
    ONCOLOGY, 2007, 73 (3-4) : 210 - 214
  • [9] Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    O'Brien, MER
    Wigler, N
    Inbar, M
    Rosso, R
    Grischke, E
    Santoro, A
    Catane, R
    Kieback, DG
    Tomczak, P
    Ackland, SP
    Orlandi, F
    Mellars, L
    Alland, L
    Tendler, C
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 440 - 449
  • [10] Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE
    de la Fouchardiere, C.
    Largillier, R.
    Goubely, Y.
    Hardy-Bessard, A. -C.
    Slama, B.
    Cretin, J.
    Orfeuvre, H.
    Paraiso, D.
    Bachelot, T.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1959 - 1963
12345